Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant

NCT01264315 | Completed Phase 2 DMC

• 2 other identifiers: RV-MM-GITMO-4132008-004529-41
• Study Type: interventional
• Target: 53
• Locations: 1 country
• Sites: 1

Brief Summary

Rationale: We recently reported a study where overall and event free survivals in newly diagnosed myeloma patients receiving an autologous transplant followed by an allograft from an HLA-identical sibling were superior as compared to those undergoing a double autologous transplant. A larger multicenter study by the Gruppo Italiano Trapianti di Midollo (GITMO), co-ordinated by our group and recently closed, employing a tandem auto-allo approach in newly diagnosed patients confirmed the achievement of prolonged event free and overall survival. Importantly, the achievement of at least very good partial remission at the time of allografting conferred a significant advantage in both event-free-survival (HR 0,23, CI 0,11-0,48; p=0,0001) and overall survival (HR 0,26; CI 0,09-0,79; p=0,02). Moreover, recent advances in the understanding of the pathogenesis of multiple myeloma have identified specific signalling pathways that have become targets for biologically-based drugs such as thalidomide, bortezomib and lenalidomide and employed in several trials, including after allograft. The aim of the current proposal is to combine the post-transplant efficacy of graft-vs.-myeloma with the anti-myeloma effect of lenalidomide in newly diagnosed myeloma patients with an HLA-identical sibling treated with a tandem autograft-allograft approach. Maintenance/consolidation of the response may be a key factor to further improve rate of clinical and molecular (as a prelude to cure) remissions and prolong overall and event free survivals after allografting. We would like to investigate the safety and efficacy of lenalidomide as consolidation/maintenance therapy in patient undergoing tandem autologous-allogeneic transplant. Objectives of study: To evaluate 1) toxicity and tolerability of lenalidomide after allografting; 2)To evaluate efficacy of lenalidomide in inducing complete remission, defined as negative immunofixation, 12 months after allografting; 3) overall-survival; 4) event-free survival; 5) molecular remission rate. Furthermore we plan to compare molecular remission rate in patients treated with lenalidomide after tandem auto-allo transplant and after double autologous transplant and to monitor minimal residual disease in patients achieving clinical CR with lenalidomide. Patient Selection: Patients with newly diagnosed multiple myeloma with an HLA identical sibling suitable for PBSC donation will be included. Complete cytogenetic analysis at diagnosis will be required. The patient must have the capacity to give informed consent. Age \>18 and \< 65. Negative pregnancy test and willing to use contraceptive techniques during and for 12 months following treatment is required. Only very unfitted patients will be excluded. Treatment plan: Lenalidomide will be started at 6 months post-allotransplant at the dose of 10 mg/day continuously in all patients (unless in molecular CR), if the following conditions are present:

• absolute neutrophil count \> 1 x 109/L without the use of growth factors;
• platelet count \> 75 x 109/L without transfusion support;
• calculated or measured creatinine clearance: ≥ 20 mL/minute;
• total bilirubin \< 2 x the upper limit of normal,
• AST and ALT \< 2.5 x upper limit of normal
• less than 1 mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD (if more immunosuppression is required to control GVHD, the maintenance therapy with lenalidomide will be held until this criteria will be satisfied) Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events are experienced or progressive disease occurs. Moreover, lenalidomide will be discontinued in patients who achieve and maintain molecular remission for 2 consecutive controls at least 6 weeks apart. Safety section - dose modification plan: During the study patients will be monitored for the occurrence of side effects. Toxicity events will be graded according to the NCI toxicity criteria. In case of severe toxicity, the lenalidomide dose will be reduced or withheld as outlined in the protocols. Statistical section: - Total patient sample size: 53. This is a phase 2 study designed according to a Simon's two-stage Minimax Design. An early stopping rule will be established to interrupt the study in case of futility (a non satisfactory response rate). In stage I 27 patients will be enrolled; if \< 14 complete remissions will be observed, the trial will be stopped. In stage II 26 more patients will be enrolled. If ≥ 32 responses will be observed, it will be concluded that the lenalidomide maintenance is active in increasing the complete remission rate after auto-allograft. Analysis plan: Toxicity monitoring will be incorporated into the study design by requiring that the trial be terminated after an initial stage if the number of observed toxicities (treatment related deaths) is excessive.

Conditions

Multiple Myeloma

Keywords

Lenalidomide; Tandem Autologous-Allogeneic Transplant

Outcome Measures

Primary Outcomes (2)

• Lenalidomide toxicity and tolerability after allografting

  To evaluate toxicity and tolerability of lenalidomide after allografting.

  6 years

• Lenalidomide efficacy

  To evaluate efficacy of lenalidomide in inducing complete remission, defined as negative immunofixation, 12 months after allografting.

  1 years

Secondary Outcomes (5)

• Overall survival

  6 years

• Progression free survival

  6 years

• Event free survival

  6 years

• Molecular remission rate

  6 years

• Minimal residual disease

  6 years

Study Arms (1)

Lenalidomide in maintenance

OTHER

Drug: Lenalidomide

Interventions

Lenalidomide DRUG

Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients: * absolute neutrophil count \>1x109/L without growth factors * platelet count \>75x109/L without transfusion support * calculated/measured creatinine clearance: ≥20mL/minute * total bilirubin \<2 x the upper limit of normal * AST (SGOT) and ALT (SGPT) \<2.5 x upper limit of normal * \<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart.

Lenalidomide in maintenance

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Newly diagnosed multiple myeloma patients with an HLA identical sibling suitable for PBSC donation and treated in induction with thalidomide or bortezomib or lenalidomide conteining regimes.
• Complete cytogenetic analysis at diagnosis, including FISH analysis for chromosome deletions 13 and 17, and translocations (4;14) (11;14) and (14;16).
• The patient must have the capacity to give informed consent.
• Age \>18 and \< 65
• If female, the patient is either postmenopausal since at least 24 consecutive months or surgically sterilized or she agrees to practice sexual abstinence or to use two reliable methods for contraception (e.g. a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide) for the duration of study
• If male, the patient agrees to practice sexual abstinence or to use a latex condom during any sexual contact with women of childbearing potential for the duration of study
• Negative pregnancy test

You may not qualify if:

• Karnofsky score less than 60 (see appendix C), unless due solely to myeloma
• Left ventricular ejection fraction less than 40%, or symptomatic coronary artery disease or other cardiac failure requiring therapy
• Bilirubin greater than 2 X the upper limit of normal, or SGPT and SGOT \> 4 X the upper limit of normal
• DLCO \< 40% (corrected) or receiving continuous supplemental oxygen.
• Creatinine clearance \< 40 cc/min at the time of initial autografting evaluation.
• Patients with poorly controlled hypertension
• Patients with active non-hematologic malignancies (except non-melanoma skin cancers).
• Patients with a history of non-hematologic malignancies (except non-melanoma skin cancers) currently in a complete remission, who are less than 5 years from the time of complete remission, and have a \>20% risk of disease recurrence
• Seropositive for HIV
• Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment.
• To evaluate toxicity and tolerability of lenalidomide after allografting
• To evaluate efficacy of lenalidomide in inducing complete remission 12 months after allografting

Sponsors & Collaborators

• Fondazione EMN Italy Onlus: lead

Study Sites (1)

A.O.U. Città della Salute e della Scienza di Torino

Torino, 10126, Italy

Location

MeSH Terms

Conditions

Multiple Myeloma

Interventions

Lenalidomide

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Phthalimides; Phthalic Acids; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals; Piperidones; Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Isoindoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Luisa Giaccone, MD

  Division of Hematology - University of Torino - A.O.U. Città della Salute e della Scienza di Torino - Torino - Italy

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 20, 2010
• First Posted: December 21, 2010
• Study Start: September 1, 2008
• Primary Completion: December 1, 2012
• Study Completion: February 1, 2023
• Last Updated: May 26, 2023

Record last verified: 2023-05

Locations

IT (1)